Novo Nordisk's oral semaglutide impresses analysts against Victoza, Januvia

Once it wins approval, Novo Nordisk’s highly anticipated oral diabetes drug semaglutide will go up against some stiff competition. But the drugmaker just showed that its up-and-comer can take the heat.